Abstracts tagged "interstitial lung disease"

Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1194 • ACR Convergence 2020
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Fabienne Louis-Sidney², Benjamin Granger³, Joanna Kedra⁴, Marie-Pierre Debray⁵, Esther Ebstein¹, Raphaël Borie⁶, Arnaud Constantin⁷, Bernard Combe⁸, Rene-Marc Flipo⁹, Xavier Mariette¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Guillermo Carvajal Alegria¹³, Jean Sibilia¹⁴, Francis Berenbaum¹⁵, Caroline Kannengiesser¹⁶, Bruno Crestani⁶, Catherine Boileau¹⁶, Bruno Fautrel¹⁷ and Philippe Dieude¹⁸, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Paris, France, ⁴Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁶Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁷Hospital Pierre Paul Riquet, Toulouse, France, ⁸University of Montpellier, Montpellier, France, ⁹Lille University Hospital, Lille, France, ¹⁰Paris-Sud University, Rueil-Malmaison, France, ¹¹University Hospital of Rouen, Rouen, France, ¹²Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹³CHU de Brest, Service de Rhumatologie, Brest, France, ¹⁴CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁵AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁶Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) detected in 20 to 60% of patients with RA on high-resolution computed-tomography…
Abstract Number: 2039 • ACR Convergence 2020
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Britany Adler¹, Ami Shah², Francesco Boin³, Paul Wolters³, Livia Casciola-Rosen⁴ and Antony Rosen¹, ¹Johns Hopkins University, baltimore, MD, ²Johns Hopkins University School of Medicine, Ellicott City, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Johns Hopkins University, Johns Hopkins University, MD
Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
Abstract Number: 0383 • ACR Convergence 2020
Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials
Elizabeth Volkmann¹, Ning Li², Michael Roth², Carol Feghali-Bostwick³, Richard Silver⁴, DeAnna Baker Frost⁵, Shervin Assassi⁶, Grace Kim², Jonathan Goldin² and Donald Tashkin², ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, ³The Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, ⁵The Medical University of South Carolina, Charleston, ⁶University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
Abstract Number: 1050 • ACR Convergence 2020
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center
Belén Atienza-Mateo¹, Sara Remuzgo-Martínez², Diana Prieto-Peña¹, Víctor Manuel Mora Cuesta³, David Iturbe-Fernández³, Sonia Fernández Rozas¹, Alfonso Corrales¹, José Manuel Cifrián² and Miguel Ángel González-Gay⁴, ¹Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: The presence of interstitial lung disease (ILD) in patients with autoimmune diseases (AD)s influences significantly on their morbidity and mortality [1]. Different treatment strategies…
Abstract Number: 1195 • ACR Convergence 2020
MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression
Pierre-Antoine Juge¹, Joshua Solomon², Romain Garofoli³, Joyce S. Lee⁴, Fabienne Louis-Sidney⁵, Esther Ebstein¹, Jorge Rojas-Serrano⁶, Montserrat I. Gonzalez-Perez⁶, Mayra Mejia⁶, Ivette Buendia-Roldan⁶, Ramces Falfan-Valencia⁷, Enrique Ambrocio-Ortiz⁷, Effrosyni Manali⁸, Spyros A. Papiris⁸, Theofanis Karageorgas⁹, Dimitrios Boumpas⁹, Katarina Antoniou¹⁰, Coline H.M. van Moorsel¹¹, Joanne van Der Vis¹¹, Yaël A. de Man¹¹, Jan C. Grutters¹¹, Caroline Kannengiesser¹², Raphaël Borie¹³, Lidwine Wemeau-Stervinou¹⁴, Rene-Marc Flipo¹⁵, Hilario Nunes¹⁶, Yurdagul Uzunhan¹⁷, Dominique Valeyre¹⁸, Nathalie Saidenberg Kermanac'h¹⁹, Marie-Christophe Boissier²⁰, Christophe Richez²¹, Thierry Schaeverbeke²², Tracy J. Doyle²³, Paul Wolters²⁴, Marie-Pierre Debray²⁵, Catherine Boileau¹², Raphaël Porcher²⁶, Bruno Crestani¹³, David A. Schwartz⁴ and Philippe Dieude²⁷, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²National Jewish Health, Denver, CO, ³Hôpital Cochin, Service de Rééducation, Paris, Paris, France, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO, ⁵Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ⁶Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, México City, México, Mexico, Mexico, ⁷HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Mexico City, Mexico, Mexico, Mexico, ⁸2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ¹⁰PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, Faculty of Medicine, University of Crete, Crete, Greece, Heraklion, Greece, ¹¹St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, The Netherlands, Nieuwegein, Netherlands, ¹²Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ¹⁴CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence des maladies pulmonaires rares, FHU IMMINENT, Lille, France, Lille, France, ¹⁵Lille University Hospital, Lille, France, ¹⁶Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ¹⁷Hôpital Avicennes, Service de Pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁸Hôpital Avicenne, Service de pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁹Hôpital Avicennes, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²⁰Hôpital Avicenne, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²¹Rheumatology Hospital, Pelligrin Hospital, Bordeaux University Hospital, Bordeaux, France, ²²CHU de Bordeaux, Service de Rhumatologie, Bordeaux, France, ²³Brigham and Women's Hospital, West Roxbury, MA, ²⁴University of California, San Francisco, San Francisco, CA, ²⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²⁶Centre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, F-75004 Paris, France, Paris, France, ²⁷Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) sharephenotypic and genotypic similarities. Recently, in a large international genetic association…
Abstract Number: 2040 • ACR Convergence 2020
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Martina Gahlemann⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Susanne Stowasser⁶ and Kristin Highland⁸, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁴University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…
Abstract Number: 1051 • ACR Convergence 2020
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
Kristin D'Silva¹, Iazsmin Bauer Ventura², Marcy Bolster³, Flavia Castelino⁴, Amita Sharma¹, Brent Little¹, Ayodeji Adegunsoye², Mary Strek², Sydney Montesi¹ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²University of Chicago, Chicago, IL, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with…
Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Austin Wheeler¹, Gail Kerr², Ilona Jileaeva³, Asha Krishna⁴, Bryant England¹, Harlan Sayles¹, Geoffrey Thiele¹, Jill Poole¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Washington DC VA Medical Center, Washington, DC, ³Howard University Hospital, Washington, DC, ⁴Washington, D.C. VAMC, Washington, DC
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
Abstract Number: 0398 • ACR Convergence 2020
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Emily Startup², Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Nora Sandorfi¹², Ami Shah¹³, Victoria Shanmugam¹⁴, Virginia Steen¹⁵ and Dinesh Khanna¹⁶, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁴The George Washington University, Washington, DC, ¹⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
Abstract Number: 1197 • ACR Convergence 2020
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Dawson Shaver¹, Daniel Van Kalsbeek¹, Ariadne Ebel¹, Daniel Hershberger¹, Cynthia Schmidt¹, Jill Poole¹, Geoffrey Thiele¹, Dana Ascherman², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is among the most frequent and severe extra-articular manifestations of RA, contributing significantly to the excess mortality among RA…
Abstract Number: 0469 • ACR Convergence 2020
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
Denny Gao¹, Maggie Henderlight¹, Christopher Woods¹, Alexei Grom¹, Sherry Thornton¹, Michael Jordan¹, Katheryn Wikenheiser-Brokamp¹ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
Abstract Number: 1053 • ACR Convergence 2020
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study
Ahmad Qurie¹, Smita Maruvada¹, Sarwat Umer¹, Jerry Mclarty² and Samina Hayat¹, ¹LSU Shreveport, Shreveport, LA, ²LSU Shreveport, Shreveport
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication associated with connective tissue diseases (CTDs), often resulting in substantial morbidity and mortality. Despite numerous advances…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].